Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. Nawwar Al-Attar
James Cox's "maze procedure", - interrupting the atrial pathways necessary for multiple reentry circuits - has set the gold standard in surgical management of AF. However, it carries a risk of significant complications and a non negligible mortality rate, therefore it has been scarcely adopted. Michel Haissaguerre since, has developed a less invasive operation using a modified Cox maze procedure - epicardial ablation of only left atrial tissues through topical application rather than the "cut-and-sew technique", while employing alternate energy sources - cryothermy, ultrasound, or radiofrequency - thereby expanding the indications of surgical ablation for AF. Patients with paroxysmal AF have given best rates of return to sinus rhythm after such procedures but patients with large left atria, prolonged duration of AF, advanced age, and associated coronary artery disease have poorer results. Conversely, patients with large left atria, prolonged duration of AF, advanced age, and associated coronary artery disease have been associated with poorer results. Anticoagulation drugs are continued for at least three months after the ablation.
Atrial fibrillation (AF) is the most frequent cardiac arrhythmia; moreover, it is associated with significant morbi-mortality. Medical treatment is accompanied with serious drug side effects and often fails to completely preclude complications of AF. Thus considerable advances in developing alternative treatments have been undertaken. Cox pioneered surgical ablation with the Maze procedure and subsequently limited left-atrial ablation lesion sets using alternative energy sources have been described with encouraging results. Indeed, atrial Fibrillation (AF) is a major public health problem: 4.5 million cases of paroxysmal and persistent AF in the EU were reported in 2004 forming around 1 % of the population. The annual cost of medical treatment per patient is 3000 € totaling 1,86 billion € for the EU. AF leads to a 1.5- to 1.9-fold increase in mortality after adjustment for the preexisting cardiovascular conditions with which AF was related. The goal of AF therapy is to achieve a return to permanent sinus rhythm; however it is interesting to note that the presence of sinus rhythm, but not anti-arrhythmic drugs, is associated with a lower risk of death.
Surgery has played a significant role in the management of AF greatly due to the work of James Cox who set the gold standard with the Maze procedure in which surgical incisions in the atrial wall interrupt the atrial pathways necessary for multiple reentry circuits (figure). Despite excellent results reported by Cox, the maze procedure is hindered by its technical complexity, risk of significant complications and a non negligible mortality rate and consequently it has been sparsely adopted. After the work of Haissaguerre showing that left atrial sources of ectopic activity are of particular importance and that arrhythmias originate from ectopic foci in the pulmonary veins up to 94 percent of the time, a less invasive operation including only left atrial lesions was described to facilitate the procedure. Furthermore, surgical incisions were replaced by new surgical approaches employing alternate energy sources to replicate the Cox maze lines of atrial conduction block more quickly.
The idea is to perform the Maze procedure by ablating atrial tissue through topical application rather than surgical incisions and suturing i.e., the classical “cut-and-sew technique” permitting faster and less invasive procedures. Again, the main idea is to create lines of intra-atrial conduction block that will :
The ideal energy source to achieve such lesions should have the following characteristics:
The following are the most common sources of energy employed in clinical use :
Radiofrequency produces heat resulting in thermal injury to the atrial tissue. It can be applied to either endocardial or epicardial heart surfaces and can be used off-pump and in minimally invasive procedures for AF. The current state of the art is bipolar radiofrequency clamps that create precise and uniform transmural lesions and give clinical success rates (return to sinus rhythm) of around 85%.
Cryoablation induces transmural lesions by freezing atrial tissue. Unlike radiofrequency there is no tissue vaporisation or charring and the endocardial surface remains smooth following cryoablation. The benefit of this technique has been illustrated by Cox who initially incorporated cryotherapy into the Cox-Maze III procedure and then performed the entire procedure solely by cryoablation: the ‘cryo-Maze’ procedure. Cryoablation is amenable to minimally invasive procedures.
High intensity focused ultrasound energy is applied epicardially on the beating heart prior to the concomitant intracardiac procedure to induce ablation lesion sets resulting in deep heating, coagulation necrosis, and conduction block. The device is an array of multiple ultrasound transducers that is used to produce a transmural circumferential left atrial lesion around the pulmonary vein orifices. An additional tool, can be used for the creation of additional linear lesions. Initial clinical results reported excellent early term return to sinus rhythm (80-100%) .
The current indications are summarised in the consensus statement of the Heart Rhythm Society.
Following surgery, a process of reverses atrial modeling “healing” takes place and is frequently accompanied by some form of arrhythmia. Despite the absence of a consensus, antiarrhythmic and anticoagulation drugs are continued for at least three months after the ablation. The criteria for their interruption are based on clinical, ECG and echocardiographic assessment at 3, 6 and 12 months and include the absence of symptoms, return to sinus rhythm and signs of recovered atrial function.
Complexity of the Cox-Maze procedure has led to development of faster, simpler, and less invasive surgical techniques employing alternative energy sources for ablation of AF. Recent advances and emerging technologies with these techniques have allowed epicardial ablation of atrial tissues on the beating heart and show great promise for application by minimally invasive techniques expanding the indications of surgical ablation for AF. Patients with paroxysmal AF often have ectopic foci originating around the pulmonary veins and have given best rates of return to sinus rhythm after such procedures. Conversely, patients with large left atria, prolonged duration of AF, advanced age, and associated coronary artery disease have been associated with poorer results. Figure. The Maze procedure. Black lines delineate surgical incisions in both the right and left atria, encircling the pulmonary veins (PV) and around the coronary artery sinus orifice. The atrial appendages are also excluded.
(MV: Mitral valve, TV Tricuspid valve, SVC: Superior vena cava, IVC: Inferior vena cava)
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.
1 - Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death. The Framingham Heart Study. Circulation 1998;98:946-52. 2 - Corley SD, Epstein AE, DiMarco JP, et al; AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management AFFIRM Study. Circulation. 2004 30;109:1509-13.
3 - Cox J.L., Schuessler R.B., Lappas D.G., Boineau J.P. An 8-year clinical experience with surgery for atrial fibrillation. Ann Thorac Surg 1996;224:267-275. 4 - Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. New Engl J Med 1998; 339: 659-66. 5 - Sueda T, Nagata H, Shikata H, et al. Simple left atrial procedure for chronic atrial fibrillation associated with mitral valve disease. Ann Thorac Surg 1996;62:1796-1800 6 - Cox JL, Schuessler RB, Boineau JP. The development of the Maze procedure for the treatment of atrial fibrillation. Seminars Thorac Cardiovasc Surg. 2000; 12: 2-14 7 - Ninet J, Roques X, Seitelberger R, et al. Surgical ablation of atrial fibrillation with off-pump, epicardial, high-intensity focused ultrasound: results of a multicenter trial. J Thorac Cardiovasc Surg. 2005;130:803-9 8 - Calkins H, Brugada J, Packer DL et al. HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2007;4:816-61. 9 - Patel VV, Ren JF, Marchlinski FE. A comparison of left atrial size by two-dimensional transthoracic echocardiography and magnetic endocardial catheter mapping. Pacing & Clinical Electrophysiology. 2002; 25:95-7.
Prof. Nawwar Al-Attar, FRCS, FETCS, PhD Hôpital Bichat, Paris, France
© 2016 European Society of Cardiology. All rights reserved